Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

The Phase III miss leaves Lipocine weighing its next steps as the field narrows to a single approved therapy for postpartum depression and limited options in development.

Catherine Owen Adams joined Acadia on the precipice of achieving a major goal – its first year with $1bn in revenue – as the company and the industry struggled to understand policy shifts under the Trump administration.

After giving up on a Phase II ulcerative colitis candidate, microbiome-focused Vedanta gets data monitoring committee approval to continue pivotal study of VE303 to prevent C. difficile recurrence.

Atrogi is betting that preserving muscle will define the next wave of obesity treatments, with its drug ATR-258 aiming to deliver exercise-like metabolic benefits.